BRPI0517460A - análogos canabinóides eficazes de administração oral - Google Patents

análogos canabinóides eficazes de administração oral

Info

Publication number
BRPI0517460A
BRPI0517460A BRPI0517460-0A BRPI0517460A BRPI0517460A BR PI0517460 A BRPI0517460 A BR PI0517460A BR PI0517460 A BRPI0517460 A BR PI0517460A BR PI0517460 A BRPI0517460 A BR PI0517460A
Authority
BR
Brazil
Prior art keywords
useful
effective
effective oral
oral cannabinoid
cannabinoid analogues
Prior art date
Application number
BRPI0517460-0A
Other languages
English (en)
Inventor
Avihai Yacovan
Avi Barjoseph
Sigal Meilin
Shimon Amselem
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of BRPI0517460A publication Critical patent/BRPI0517460A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

ANALOGOS CANABINóIDES EFICAZES DE ADMINISTRAçãO ORAL. A presente invenção está relacionada a ligantes oralmente eficazes de canabinóide periférico do mesmo, receptor CB~ 2~, especialmente derivados de (+) - <244> - pineno, e às suas composições farmacêuticas, as quais são úteis para a prevenção, alívio ou tratamento de distúrbios autoimunes neurodegenerativos, em particular esclerose múltipla e sintomas associados. Os métodos da invenção são úteis quando o ingrediente ativo é administrado sozinho ou em combinação com modalidades terapêuticas existentes. As composições são administradas por via oral.
BRPI0517460-0A 2004-10-22 2005-02-24 análogos canabinóides eficazes de administração oral BRPI0517460A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62071604P 2004-10-22 2004-10-22
PCT/IL2005/000231 WO2006043260A2 (en) 2004-10-22 2005-02-24 Orally effective cannabinoid analogs

Publications (1)

Publication Number Publication Date
BRPI0517460A true BRPI0517460A (pt) 2008-10-07

Family

ID=36203335

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517460-0A BRPI0517460A (pt) 2004-10-22 2005-02-24 análogos canabinóides eficazes de administração oral

Country Status (10)

Country Link
US (1) US20090068143A1 (pt)
EP (1) EP1802293A4 (pt)
JP (1) JP2008517901A (pt)
KR (1) KR20070083903A (pt)
CN (1) CN101076324A (pt)
AU (1) AU2005297249A1 (pt)
BR (1) BRPI0517460A (pt)
CA (1) CA2584550A1 (pt)
WO (1) WO2006043260A2 (pt)
ZA (1) ZA200703517B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535238A (ja) * 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
EP2415765A4 (en) 2009-03-30 2012-08-15 Astellas Pharma Inc PYRIMIDINE COMPOUND
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
WO2017185038A1 (en) 2016-04-22 2017-10-26 Receptor Life Sciences Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208351A (en) * 1976-11-10 1980-06-17 Eli Lilly And Company Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor
IL55274A (en) * 1978-08-02 1982-08-31 Yissum Res Dev Co 4-(2,6-dihydroxy-4-(dimethylheptyl)phenyl)substituted 2-pinen-10-ol and pinane derivatives,their preparation and pharmaceutical compositions comprising them
US5434295A (en) * 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
AU785033B2 (en) * 1999-10-18 2006-08-31 University Of Connecticut, The Novel bicyclic cannabinoid agonists for the cannabinoid receptor
JP2005523259A (ja) * 2002-01-31 2005-08-04 ファーモス コーポレイション 二環式ｃｂ２カンナビノイド受容体リガンド
IL147941A0 (en) * 2002-01-31 2002-08-14 Pharmos Corp Bicyclic cb2 cannabinoid receptor ligands

Also Published As

Publication number Publication date
EP1802293A2 (en) 2007-07-04
ZA200703517B (en) 2008-08-27
AU2005297249A1 (en) 2006-04-27
WO2006043260A3 (en) 2006-05-26
CA2584550A1 (en) 2006-04-27
WO2006043260A2 (en) 2006-04-27
CN101076324A (zh) 2007-11-21
JP2008517901A (ja) 2008-05-29
KR20070083903A (ko) 2007-08-24
US20090068143A1 (en) 2009-03-12
EP1802293A4 (en) 2009-04-29

Similar Documents

Publication Publication Date Title
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
BRPI0517460A (pt) análogos canabinóides eficazes de administração oral
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
HN2011001358A (es) Moduladores de aril metil benzoquinazolina alostericos positivos del receptor m1
BRPI0512514A (pt) composto, antagonista para receptores de crf, e, uso de um composto
WO2005089803A3 (en) Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
BRPI0518741A2 (pt) uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
TW200734338A (en) 6-Phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
HRP20140591T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
JP2014508758A5 (pt)
BRPI0510855A (pt) medicamento em forma de pelìcula para ministração oral e uso de estriol e/ou de ésteres de estriol farmaceuticamente aceitáveis
BR112019002655A2 (pt) composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora
ES2641143T3 (es) Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina
Metry et al. Lornoxicam with low-dose ketamine versus pethidine to control pain of acute renal colic
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
JP2004534821A5 (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.